Contact Information: Contact: Zackary Irani 949-645-2111
Biomerica Announces Third Quarter Financial Results
Operating Income up Over 33% for the 9 Months Ended February 29, 2008
| Source: Biomerica
NEWPORT BEACH, CA--(Marketwire - April 15, 2008) - Biomerica, Inc. (OTCBB : BMRA ) today
reported results of net income for the nine months ended February 29, 2008
of $1,012,588 versus a net income of $264,521 during the same period in the
previous fiscal year, an increase of $748,067. Operating income from
continued operations for the nine months ended February 29, 2008 was
$340,166 compared to operating income from continued operations of $255,113
for the same period in fiscal 2007, an increase of over 33%. The results
of net income for the three months ended February 29, 2008 was $123,844,
compared to net income of $121,370 in the same quarter the previous fiscal
year. Operating income from continued operations for the quarter ended
February 29, 2008 was $118,009 compared to operating income from continued
operation of $95,756 for the same period in fiscal 2007, an increase of
over 23%.
Biomerica announced results of net sales of $1,240,809 for the third
quarter fiscal 2008 ended February 29, 2008, compared to net sales of
$1,311,609 in fiscal 2007. Net sales for the first nine months of fiscal
2008 were $3,608,408 compared to net sales of $3,797,051 for the first nine
months in fiscal 2007. The primary result of the decrease in sales was due
to the loss of one large customer in Australia.
"As we close the thirteenth consecutive quarter of profitability, we
continue to make progress in expanding our international distribution and
developing new distribution relationships in the domestic market," stated
Zackary Irani, Biomerica CEO. "We remain excited about the growth
prospects in our diagnostic business."
About Biomerica (OTCBB : BMRA )
Biomerica, Inc. (http://www.biomerica.com) is a global medical technology
company, based in Newport Beach, CA. The Company's diagnostics division
manufactures and markets advanced diagnostic products used at home, in
hospitals, and in physicians' offices for the early detection of
significant medical conditions and serious diseases.
Certain information included in this press release (as well as information
included in oral statements or other written statements made or to be made
by Biomerica) contains statements that are forward-looking: such as
statements relating to intended improvements to the Company's financial
performance, continued growth in business, launch dates, expansion,
expected orders, growth prospects, leading market positions, anticipated
future sales revenues of the company, success of product(s) and new product
introductions. Such forward-looking information involves important risks
and uncertainties that could significantly affect anticipated results in
the future, and accordingly, such results may differ materially from those
expressed in any forward-looking statements made by or on behalf of
Biomerica. The potential risks and uncertainties include, among others,
fluctuations in the Company's operating results due to its new business
model and expansion plans, the Company's ability to raise additional
capital, the competitive environment in which the Company will be
competing, and the Company's dependence on strategic relationships. The
Company is under no obligation to update any forward-looking statements
after the date of this release.